Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,190.00
Bid: 12,210.00
Ask: 12,214.00
Change: 162.00 (1.35%)
Spread: 4.00 (0.033%)
Open: 12,036.00
High: 12,214.00
Low: 12,024.00
Prev. Close: 12,028.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 3-G7 vaccine pledge is just a drop in the ocean, campaigners say

Fri, 11th Jun 2021 07:37

* G7 to pledge 1 billion vaccine doses

* Campaigners say G7 too slow, lacks ambition

* Britain to give 100 million doses

* UK says some countries using vaccines to exert influence
(Adds quotes from former UK PM Brown, Canadian pledge)

By Kate Holton and Elizabeth Piper

CARBIS BAY, England, June 11 (Reuters) - A Group of Seven
plan to donate 1 billion COVID-19 vaccine doses to poorer
countries lacks ambition, is far too slow and shows Western
leaders are not yet up to the job of tackling the worst public
health crisis in a century, campaigners said on Friday.

British Prime Minister Boris Johnson said he expected G7
leaders to agree the donations as part of a plan to inoculate
the world's nearly 8 billion people against the coronavirus by
the end of next year.

After U.S. President Joe Biden vowed to supercharge the
fight against the virus with a donation of 500 million Pfizer
shots, Johnson said Britain would give at least 100
million vaccines within a year.

Canada is expected to commit to sharing up to 100 million
doses. Other pledges may follow.

But health and anti-poverty campaigners said that, while
donations were a step in the right direction, Western leaders
had failed to grasp the exceptional efforts needed to beat the
virus. Help with distribution was also necessary, they said.

Former British prime minister Gordon Brown, who has been
pushing for richer countries to share more of the cost of
vaccinating developing countries, said the G7 pledges were more
akin to "passing round the begging bowl" than a real solution.

"It's a catastrophic failure if we can't go away in the next
week or two ... with a plan that actually rids the world of
COVID now we've got a vaccine," he told Reuters.

Alex Harris at Wellcome, a London-based science and health
charitable foundation, said the pledges did not go far enough.

"What the world needs is vaccines now, not later this year.
At this historic moment, the G7 must show the political
leadership our crisis demands," said Harris. "We urge G7 leaders
to raise their ambition."

The race to end a pandemic that has killed around 3.9
million people and sown social and economic destruction will
feature prominently at the three-day summit which began on
Friday in the English seaside resort of Carbis Bay.

British foreign minister Dominic Raab warned that other
countries were using vaccines as diplomatic tools to secure
influence. Britain and the United States said their
donations would come with no strings attached.

COVID-19 has ripped through the global economy, with
infections reported in more than 210 countries and territories
since the first cases were identified in China in December 2019.

'FAILURE'

As most people need two vaccine doses, and possibly booster
shots to tackle emerging variants, campaigners said world
leaders needed to go much further, and much faster.

"If the best G7 leaders can manage is to donate 1 billion
vaccine doses then this summit will have been a failure,"
Oxfam's health policy manager Anna Marriott said, adding that
the world would need 11 billion doses to end the pandemic.

Vaccination efforts so far are heavily correlated with
wealth: the United States, Europe, Israel and Bahrain are far
ahead of other countries. A total of 2.2 billion people have
been vaccinated according to Johns Hopkins University data.

Oxfam also called on G7 leaders to support a waiver on the
intellectual property behind the vaccines.

French President Emmanuel Macron has said intellectual
property rights should not hinder access to vaccines during a
pandemic, appearing to back Biden on the subject.

VACCINE OWNERSHIP?

But the pharmaceutical industry has opposed it, saying it
would stifle innovation and do little to increase supplies.
Britain, which backed Oxford-AstraZeneca's
not-for-profit shot, has said a patent waiver is not necessary.

Of the 100 million British shots, 80 million will go to the
COVAX programme led by the World Health Organization (WHO) and
the rest will be shared bilaterally with countries in need.

Johnson echoed Biden in calling on his fellow leaders to
make similar pledges and for pharmaceutical companies to adopt
the not-for-profit model during the pandemic. The U.S. Pfizer
donations will be supplied at cost.

Mass vaccination against the novel coronavirus is seen as
crucial to restoring economic growth and preventing the virus
from further mutation that could evade vaccines.

The British doses will be drawn from the stock it has
already procured for its domestic programme, and will come from
suppliers Oxford-AstraZeneca, Pfizer-BioNTech, Johnson &
Johnson's Janssen, Moderna and others.

(Additional reporting by Alistair Smout in London and David
Ljunggren in Ottawa; Editing by Guy Faulconbridge, Alex
Richardson and Emelia Sithole-Matarise)

More News
23 Oct 2023 08:45

TOP NEWS: AstraZeneca says Enhertu approved by European Commission

(Alliance News) - AstraZeneca PLC on Monday said its Enhertu treatment has been approved by the European Commission to treat adult lung cancer patients.

Read more
23 Oct 2023 07:46

LONDON BRIEFING: Keller expects higher profit; Upland rejects approach

(Alliance News) - Stocks in London are set to open slightly higher on Monday, as risk sentiment improves after a difficult period for markets last week.

Read more
18 Oct 2023 09:04

AstraZeneca drug Solaris approved in China as NMOSD treatment

(Alliance News) - AstraZeneca PLC on Wednesday announced that eculizumab, whose brand name is Solaris, has been approved in China to treat patients with neuromyelitis optica spectrum disorder

Read more
17 Oct 2023 12:06

LONDON MARKET MIDDAY: European markets uneasy but FTSE 100 outperforms

(Alliance News) - London's FTSE 100 higher was higher around midday, though it was defensive stocks such as utilities and pharmaceuticals which led the charge, suggesting there is still lingering discomfort in markets amid tensions in the Middle East.

Read more
16 Oct 2023 08:34

TOP NEWS: AstraZeneca's cancer drug gets priority review from US FDA

(Alliance News) - AstraZeneca PLC on Monday said that its new drug application for Tagrisso has been granted priority review in the US, after trial results extended progression-free survival.

Read more
4 Oct 2023 12:14

IN BRIEF: AstraZeneca's Forxiga drug shows positive results in trial

AstraZeneca PLC - Cambridge-based pharmaceutical maker - Says Forxiga drug meets primary endpoints in T2NOW phase three trial and shows "clinically meaningful" improvements in the glycaemic control among type two diabetes patients between the ages of 10 and 17. Adds safety results in patient cohort were consistent with those in adults with type two diabetes.

Read more
3 Oct 2023 16:55

LONDON MARKET CLOSE: Stocks red as rate rise fears continue to grow

(Alliance News) - Stocks in London were lower at the close on Tuesday after unexpectedly strong US job openings data added to fears that interest rates in the world's largest economy will stay higher for longer.

Read more
3 Oct 2023 11:59

LONDON MARKET MIDDAY: HSBC and StanChart help FTSE 100 outperform

(Alliance News) - London's FTSE 100 grew in confidence as Tuesday morning progressed, going into the afternoon in the green and outperforming European peers.

Read more
3 Oct 2023 08:36

TOP NEWS: AstraZeneca settles Nexium and Prilosec litigation

(Alliance News) - AstraZeneca PLC on Tuesday said it has settled legal matters involving its Nexium acid reflux and Prilosec heartburn products, parting with USD425 million.

Read more
3 Oct 2023 07:41

LONDON BRIEFING: Greggs sales rise; boohoo cuts revenue outlook

(Alliance News) - London's FTSE 100 is set to fall further on Tuesday, after a sell-off at the start of the week, with hawkish words from a US central banker reinforcing the 'higher-for-longer' interest rates messaging.

Read more
3 Oct 2023 07:24

AstraZeneca agrees to settle most Nexium, Prilosec claims

(Sharecast News) - Global pharmaceutical company AstraZeneca has agreed to settle litigation on product liability related to two of its widely-used heartburn drugs, Nexium and Prilosec, it announced on Tuesday.

Read more
25 Sep 2023 09:13

LONDON BROKER RATINGS: Jefferies raises AstraZeneca to 'buy'

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning:

Read more
25 Sep 2023 07:43

LONDON BRIEFING: Stocks seen lower; Aviva buys AIG's UK protection arm

(Alliance News) - Stocks in London were set to open lower on Monday as investors eyed fresh concerns for the already fragile Chinese property sector.

Read more
22 Sep 2023 08:42

LONDON MARKET OPEN: Stocks slip after central bank rate calls

(Alliance News) - Stock prices in London opened lower on Friday, but managed to avoid the steep declines seen in New York, as investors mulled over an eventful week dominated by central bank decisions.

Read more
22 Sep 2023 08:13

TOP NEWS: AstraZeneca's datopotamab deruxtecan shows positive results

(Alliance News) - AstraZeneca PLC on Friday said phase three data showed that datopotamab deruxtecan delivered improvement in progression-free survival in breast cancer patients.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.